# EDGAR Filing Document

**Accession Number:** 0001678660
**File Stem:** 0000950170-23-002427
**Filing Date:** 2023-2
**Character Count:** 16676
**Document Hash:** f764dad1f884ea29dcf780d6bd05ade1
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000950170-23-002427.hdr.sgml**: 20230210

**ACCESSION NUMBER**: 0000950170-23-002427

**CONFORMED SUBMISSION TYPE**: SC 13G/A

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20230210

**DATE AS OF CHANGE**: 20230210

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Prelude Therapeutics Inc
- **CENTRAL INDEX KEY:** 0001678660
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 811384762
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SC 13G/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-91717
- **FILM NUMBER:** 23608593

**BUSINESS ADDRESS:**
- **STREET 1:** 200 POWDER MILL ROAD
- **CITY:** WILMINGTON
- **STATE:** DE
- **ZIP:** 19803
- **BUSINESS PHONE:** (302) 547-3768

**MAIL ADDRESS:**
- **STREET 1:** 200 POWDER MILL ROAD
- **CITY:** WILMINGTON
- **STATE:** DE
- **ZIP:** 19803

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Prelude Therapeutics Inc.
- **DATE OF NAME CHANGE:** 20160630
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Vaddi Krishna
- **CENTRAL INDEX KEY:** 0001824633

**FILING VALUES:**
- **FORM TYPE:** SC 13G/A

**MAIL ADDRESS:**
- **STREET 1:** C/O PRELUDE THERAPEUTICS INCORPORATED
- **STREET 2:** 200 POWDER MILL ROAD
- **CITY:** WILMINGTON
- **STATE:** DE
- **ZIP:** 19803

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

**Schedule 13G/A**

**Under the Securities Exchange Act of 1934**

**(Amendment No. 2)\***

**Prelude Therapeutics Incorporated**

**(Name of Issuer)** 

**Common Stock, par value $0.0001 per share** 

**(Title of Class of Securities)** 

**74065P101** 

**(CUSIP Number)** 

**December 31, 2022** 

**(Date of Event Which Requires Filing of this Statement)** 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

---

| | | |
|:---|:---|:---|
| ☐ | ☐ | Rule 13d-1(b)  |
| ☐ | ☐ | Rule 13d-1(c)  |
| ☒ | ☒ | Rule 13d-1(d)  |
| \* | The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.  | The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.  |

---

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

(Continued on following pages)

------

CUSIP #74065P101 Schedule 13G Page 2 of 6

---

| | | | | |
|:---|:---|:---|:---|:---|
| 1  |  | NAME OF REPORTING PERSONS<br>Krishna Vaddi  | NAME OF REPORTING PERSONS<br>Krishna Vaddi  | NAME OF REPORTING PERSONS<br>Krishna Vaddi  |
| 2 |  | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP<br>(a) ☐ (b) ☐ | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP<br>(a) ☐ (b) ☐ | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP<br>(a) ☐ (b) ☐ |
| 3 |  | SEC USE ONLY | SEC USE ONLY | SEC USE ONLY |
| 4 |  | CITIZENSHIP OR PLACE OF ORGANIZATION<br>United States | CITIZENSHIP OR PLACE OF ORGANIZATION<br>United States | CITIZENSHIP OR PLACE OF ORGANIZATION<br>United States |
| NUMBER OF<br>SHARES<br>BENEFICIALLY <br>OWNED BY<br>EACH<br>REPORTING<br>PERSON<br>WITH | NUMBER OF<br>SHARES<br>BENEFICIALLY <br>OWNED BY<br>EACH<br>REPORTING<br>PERSON<br>WITH | NUMBER OF<br>SHARES<br>BENEFICIALLY <br>OWNED BY<br>EACH<br>REPORTING<br>PERSON<br>WITH | 5  | SOLE VOTING POWER<br>4,299,323(1) |
| NUMBER OF<br>SHARES<br>BENEFICIALLY <br>OWNED BY<br>EACH<br>REPORTING<br>PERSON<br>WITH | NUMBER OF<br>SHARES<br>BENEFICIALLY <br>OWNED BY<br>EACH<br>REPORTING<br>PERSON<br>WITH | NUMBER OF<br>SHARES<br>BENEFICIALLY <br>OWNED BY<br>EACH<br>REPORTING<br>PERSON<br>WITH | 6 | SHARED VOTING POWER<br>0 |
| NUMBER OF<br>SHARES<br>BENEFICIALLY <br>OWNED BY<br>EACH<br>REPORTING<br>PERSON<br>WITH | NUMBER OF<br>SHARES<br>BENEFICIALLY <br>OWNED BY<br>EACH<br>REPORTING<br>PERSON<br>WITH | NUMBER OF<br>SHARES<br>BENEFICIALLY <br>OWNED BY<br>EACH<br>REPORTING<br>PERSON<br>WITH | 7 | SOLE DISPOSITIVE POWER<br>4,299,323(1) |
| NUMBER OF<br>SHARES<br>BENEFICIALLY <br>OWNED BY<br>EACH<br>REPORTING<br>PERSON<br>WITH | NUMBER OF<br>SHARES<br>BENEFICIALLY <br>OWNED BY<br>EACH<br>REPORTING<br>PERSON<br>WITH | NUMBER OF<br>SHARES<br>BENEFICIALLY <br>OWNED BY<br>EACH<br>REPORTING<br>PERSON<br>WITH | 8 | SHARED DISPOSITIVE POWER<br>0 |
| 9  |  | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON<br>4,299,323 (1) | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON<br>4,299,323 (1) | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON<br>4,299,323 (1) |
| 10 |  | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES<br>☐ | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES<br>☐ | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES<br>☐ |
| 11 |  | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9<br>11.3%(2) | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9<br>11.3%(2) | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9<br>11.3%(2) |
| 12 |  | TYPE OF REPORTING PERSON<br>IN | TYPE OF REPORTING PERSON<br>IN | TYPE OF REPORTING PERSON<br>IN |
| (1) | (1) | Consists of (i) 2,651,453 shares of voting common stock held by the Reporting Person, of which (a) 144,116 shares are unvested as of December 31, 2022, and subject to forfeiture to the Issuer if the Reporting Person ceases to provide service to the Issuer prior to the vesting of the shares and (b) 1,597,934 shares of voting common stock are subject to options that are exercisable within 60 days of December 31, 2022, (ii) 120,665 shares of voting common stock held by Sidus Ventures, LLC, (iii) 423,655 shares of voting common stock held by Dolphin City Trust, (iv) 551,776 shares of voting common stock held by Blue Sky Trust and (v) 551,774 shares of voting common stock held by Brocade Trust. The Reporting Person is the manager of Sidus Ventures, LLC and may be deemed to have beneficial ownership over the securities held by Sidus Ventures, LLC. The Reporting Person is the beneficiary of Dolphin City Trust and may be deemed to have beneficial ownership over the securities held by Dolphin City Trust. The Reporting Person is the investment advisor for each of the Blue Sky Trust and the Brocade Trust, and may be deemed to have beneficial ownership over the securities held by each of the Blue Sky Trust and the Brocade Trust. | Consists of (i) 2,651,453 shares of voting common stock held by the Reporting Person, of which (a) 144,116 shares are unvested as of December 31, 2022, and subject to forfeiture to the Issuer if the Reporting Person ceases to provide service to the Issuer prior to the vesting of the shares and (b) 1,597,934 shares of voting common stock are subject to options that are exercisable within 60 days of December 31, 2022, (ii) 120,665 shares of voting common stock held by Sidus Ventures, LLC, (iii) 423,655 shares of voting common stock held by Dolphin City Trust, (iv) 551,776 shares of voting common stock held by Blue Sky Trust and (v) 551,774 shares of voting common stock held by Brocade Trust. The Reporting Person is the manager of Sidus Ventures, LLC and may be deemed to have beneficial ownership over the securities held by Sidus Ventures, LLC. The Reporting Person is the beneficiary of Dolphin City Trust and may be deemed to have beneficial ownership over the securities held by Dolphin City Trust. The Reporting Person is the investment advisor for each of the Blue Sky Trust and the Brocade Trust, and may be deemed to have beneficial ownership over the securities held by each of the Blue Sky Trust and the Brocade Trust. | Consists of (i) 2,651,453 shares of voting common stock held by the Reporting Person, of which (a) 144,116 shares are unvested as of December 31, 2022, and subject to forfeiture to the Issuer if the Reporting Person ceases to provide service to the Issuer prior to the vesting of the shares and (b) 1,597,934 shares of voting common stock are subject to options that are exercisable within 60 days of December 31, 2022, (ii) 120,665 shares of voting common stock held by Sidus Ventures, LLC, (iii) 423,655 shares of voting common stock held by Dolphin City Trust, (iv) 551,776 shares of voting common stock held by Blue Sky Trust and (v) 551,774 shares of voting common stock held by Brocade Trust. The Reporting Person is the manager of Sidus Ventures, LLC and may be deemed to have beneficial ownership over the securities held by Sidus Ventures, LLC. The Reporting Person is the beneficiary of Dolphin City Trust and may be deemed to have beneficial ownership over the securities held by Dolphin City Trust. The Reporting Person is the investment advisor for each of the Blue Sky Trust and the Brocade Trust, and may be deemed to have beneficial ownership over the securities held by each of the Blue Sky Trust and the Brocade Trust. |
| (2) | The percentage reported in row 11 is calculated in accordance with Rule 13d-3 based on the aggregate number of shares of common stock beneficial owned by the Reporting Person and an aggregate of 36,496,994 shares of common stock entitled to vote outstanding as of December 31, 2022, as reported by the Issuer to the Reporting Person, plus the number of shares of stock options held by the Reporting Person that are exercisable within 60 days of December 31, 2022, which are treated as converted into common stock only for the purpose of computing the percentage ownership of the Reporting Person.  | The percentage reported in row 11 is calculated in accordance with Rule 13d-3 based on the aggregate number of shares of common stock beneficial owned by the Reporting Person and an aggregate of 36,496,994 shares of common stock entitled to vote outstanding as of December 31, 2022, as reported by the Issuer to the Reporting Person, plus the number of shares of stock options held by the Reporting Person that are exercisable within 60 days of December 31, 2022, which are treated as converted into common stock only for the purpose of computing the percentage ownership of the Reporting Person.  | The percentage reported in row 11 is calculated in accordance with Rule 13d-3 based on the aggregate number of shares of common stock beneficial owned by the Reporting Person and an aggregate of 36,496,994 shares of common stock entitled to vote outstanding as of December 31, 2022, as reported by the Issuer to the Reporting Person, plus the number of shares of stock options held by the Reporting Person that are exercisable within 60 days of December 31, 2022, which are treated as converted into common stock only for the purpose of computing the percentage ownership of the Reporting Person.  | The percentage reported in row 11 is calculated in accordance with Rule 13d-3 based on the aggregate number of shares of common stock beneficial owned by the Reporting Person and an aggregate of 36,496,994 shares of common stock entitled to vote outstanding as of December 31, 2022, as reported by the Issuer to the Reporting Person, plus the number of shares of stock options held by the Reporting Person that are exercisable within 60 days of December 31, 2022, which are treated as converted into common stock only for the purpose of computing the percentage ownership of the Reporting Person.  |

---

------

CUSIP #74065P101 Schedule 13G Page 3 of 6

SCHEDULE 13G

---

| | |
|:---|:---|
| CUSIP #74065P101 | CUSIP #74065P101 |
| ITEM 1(A). | <u>NAME OF ISSUER:</u>  |

---

Prelude Therapeutics Incorporated (the "Issuer")

ITEM 1(B). <u>ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:</u> 

200 Powder Mill Road

Wilmington, DE 19803

ITEM 2(A). <u>NAME OF PERSONS FILING</u> 

Krishna Vaddi (the "Reporting Person")

ITEM 2(B). <u>ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:</u> 

The address of the principal business office of the Reporting Person is:

c/o Prelude Therapeutics Incorporated

200 Powder Mill Road

Wilmington, DE 19803

ITEM 2(C). <u>CITIZENSHIP:</u> 

United States

ITEM 2(D). <u>TITLE OF CLASS OF SECURITIES:</u> 

Common Stock, par value $0.0001 per share

ITEM 2(E) <u>CUSIP NUMBER:</u> 

74065P101

ITEM 3. <u>IF THIS STATEMENT IS FILED PURSUANT TO RULE 13D-1(B), OR 13D-2(B) OR (C), CHECK WHETHER THE PERSON FILING IS A:</u> 

&nbsp;&nbsp;&nbsp;&nbsp;(a) &nbsp;&nbsp;&nbsp;&nbsp; Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);

&nbsp;&nbsp;&nbsp;&nbsp;(b) &nbsp;&nbsp;&nbsp;&nbsp; Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

&nbsp;&nbsp;&nbsp;&nbsp;(c) &nbsp;&nbsp;&nbsp;&nbsp; Insurance company as defined in section 3(a)19) of the Act (15 U.S.C. 78c);

&nbsp;&nbsp;&nbsp;&nbsp;(d) &nbsp;&nbsp;&nbsp;&nbsp; Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);

&nbsp;&nbsp;&nbsp;&nbsp;(e) &nbsp;&nbsp;&nbsp;&nbsp; An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) &nbsp;&nbsp;&nbsp;&nbsp; An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

&nbsp;&nbsp;&nbsp;&nbsp;(g) &nbsp;&nbsp;&nbsp;&nbsp; A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);

&nbsp;&nbsp;&nbsp;&nbsp;(h) &nbsp;&nbsp;&nbsp;&nbsp; A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) &nbsp;&nbsp;&nbsp;&nbsp; A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

------

CUSIP #74065P101 Schedule 13G Page 4 of 6

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(j) | &nbsp;&nbsp;&nbsp;&nbsp; A non-U.S. institution in accordance with §240.13d–1(b)(1)(ii)(J); |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(k) | &nbsp;&nbsp;&nbsp;&nbsp; Group, in accordance with §240.13d–1(b)(1)(ii)(K). |
|  | &nbsp;&nbsp;&nbsp;&nbsp;If filing as a non-U.S. institution in accordance with §240.13d–1(b)(1)(ii)(J), please specify the type of institution:________________________________. |

---

Not applicable.

ITEM 4. <u>OWNERSHIP:</u> 

(a) <u>Amount beneficially owned</u>:

See Row 9 of cover page for each Reporting Person.

(b) <u>Percent of Class</u>:

See Row 11 of cover page for each Reporting Person.

(c) <u>Number of shares as to which such person has</u>:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) <u>Sole power to vote or to direct the vote</u>:

See Row 5 of cover page for each Reporting Person.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) <u>Shared power to vote or to direct the vote</u>:

See Row 6 of cover page for each Reporting Person.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) <u>Sole power to dispose or to direct the disposition of</u>:

------

CUSIP #74065P101 Schedule 13G Page 5 of 6

See Row 7 of cover page for each Reporting Person.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) <u>Shared power to dispose or to direct the disposition of</u>:

See Row 8 of cover page for each Reporting Person.

### ITEM 5. <u>OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS:</u> 
Not applicable.

### ITEM 6. <u>OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON:</u> 
Not applicable.

ITEM 7. <u>IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY:</u> 

Not applicable.

ITEM 8. <u>IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP</u>:

Not applicable.

ITEM 9. <u>NOTICE OF DISSOLUTION OF GROUP:</u> 

Not applicable.

ITEM 10. <u>CERTIFICATION:</u> 

Not applicable.

------

CUSIP #74065P101 Schedule 13G Page 6 of 6

<u>SIGNATURES</u> 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: February 10, 2023

---

| | |
|:---|:---|
| By: | /s/ Krishna Vaddi |
|  | Krishna Vaddi |

---

------